The Skinny on Fatness, Part 3: The Interplay of Hormones and VAT

Part 3 of this series examines the role of exercise in countering metabolic syndrome.

Trying to figure out “a given cause” to Metabolic Syndrome would prove fruitless because of the large number of factors involved and how they actually have mutual influences. Exercise, itself, has several very positive effects in the body including a release of testosterone primarily in response to muscle building activities and an increased fatty acid uptake and oxidation primarily in response to endurance training. Both of these mechanisms operate in the other exercise modality but to a lesser degree. It seems that the hormone testosterone has opposite effects in men and women in regards to VAT obesity. In men, both the plasma total and free testosterone, and sex-hormone binding globulin (SHBG) concentrations are all significantly negatively correlated to VAT amounts. Young men below 30 have high testosterone and low amounts of VAT. As men age, the “pot belly” can often kick in and so does their risk of CHD. In women, however, the levels of the same three factors negatively associated with testerone are positively associated with it.

Weight loss in both sexes has been shown to reverse testosterone abnormalities and testosterone administration in men significantly lowers the VAT.27,28 Research shows testosterone secretion occurs in proportion to the intensity, not volume or duration of exercise.29 Another study found increases in testosterone with high intensity exercise resistance training but no response of cortisol. This same study observed certain dietary changes to also affect resting (pre-exercise) testosterone levels but not cortisol. The nutritional variables associated with testosterone is almost the exact opposite of many body builder regimens. They found the amount of monosaturated, polyunsaturated fatty acids, total fat to be positively associated and percent protein, protein/ CHO ratio, and poly to mono FA ratio to be negatively correlated. Investigators felt due to variability in dietary intake further research would be needed to confirm the findings.30

A “hormonal cousin” to testosterone is growth hormone. While growth hormone is responsible for growth during childhood and puberty, it fulfills several roles throughout our lives including the deposition of muscle and the oxidation of fat. It is the best of both worlds in this regard. Many studies have shown GH to increase Another key player in this metabolic syndrome game is an enzyme which is responsible for converting inactive cortisone into the active form-cortisol. The enzyme 11-ß- hydroxysteroid dehydrogenase type 1 (11-ß-HSD1) is much more active in VAT vs. SCAT. It just so happens that cortisol is also a major inhibitor of testosterone. This is literally a “double whammy” to increase the VAT which further increases the potential cortisol conversion.32

Finally, exercise may have a role by combating the fat deposited in muscle known as intramyocellular lipid- IMCL) which affects the capacity of muscle to oxidize fats thus contributing to weight gain, and potentially insulin resistance. Research showed that the amount of VAT, not SCAT, was related to the amount of skeletal muscle insulin resistance, in type 2 diabetics.33

Another study confirmed this in pre-menopausal women.34 Researchers insulin sensitivity and FFA utilization or oxidation by muscle were reduced in relation to VAT. This findings confirmed the role IMCL deposition and VAT may play in impaired oxidation of nonadipose tissue and insulin resistance and metabolic syndrome. Exercise training is associated with decreased ICML, increased FFA uptake and utilization and VAT reduction.

 

Figure 3-1 shows the inter-related effects of exercise on potential causes of VAT accumulation and metabolic syndrome onset.

As one can clearly see, there is no single answer to resolving the obesity problem in the U.S. or throughout the world.

However, there are some tips and directions we can steer our clients to reduce the risk of mortality associated with obesity and metabolic syndrome. The influences of proper exercise and diet are absolutely critical in this fight.

The higher the intensity the exercise the greater release of testosterone, growth hormone which are considered beneficial in the fight against VAT. As intensity increases so does carbohydrate oxidation which enhances the bodies capacity to store more as glycogen and lowers blood glucose in the long-term.

Likewise, diets lower in carbohydrate and in particular glycemic index or load seem to be beneficial as well. Many new developments constantly arise on this topic, so stay tuned and stay informed.

References

1) Kim SK, Kim HJ, Hur KY, Choi SH, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Cha BS: Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but the also risks of cardiovascular and metabolic diseases. Am J Clin Nutr 2004, 79: 593-599.

2) Lamarch B: Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis 1998, 9:473-481.

3) Blair D, HabrichtJP, Sims EA, Slyvester D, Abraham S: Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk. Am. J. Epidemiol 1984, 119: 526-540.

4) Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shoefer JB, Fish BE, Knopp RH, Kahn SE: Intra-abdominal fat is a major determinate of the National Cholesterol Education Program-Adult Treatment Panel III Criteria for metabolic syndrome. Diabetes 2004, 53:1195-1200.

5) Cameron AJ, Shaw JE, Zimmet PZ: The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2006; 28: 629-636

6) Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome amount U.S. adults. Diabetes Care 2004; 27: 2444-2449.

7) McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G: Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med, 2003, 139: 802-809.

8) Reaven GM: Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor’s clothes fit? Diabetes Care, 2004, 27: 1011-1012.

9) Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults- Findings from the Third National Health and Nutrition Examination Survey. J Am Med Assoc 2002,287: 356-359.

10) Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Murashima S, Maruyama N, Morioka K, Nakatani K, Yano Y, Adachi Y: Increased visceral fat and serum levels of triglycerides are associated with insulin resistance in Japenese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care, 2003, 26: 2341-2344.

11) Ruderman N, Chisholm D,Pi-Sunyer X, Schneider S: The metabolically obese, normal weight individual revisited. Diabetes 1998, 47: 699-713.

12) Fain JN, Madan AK, Hiler ML, Cheema P, Balhouth SW: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissue of obese humans. Endocrinology 2004, 145: 2273-2282.

13) Pantanetti P, Garrapa GG, Mantero F, Boscaro M, Faloia E, Venarucci D: Adipose tissue as an endocrine organ? A review of the recent data related to cardiovascular complications of endocrine dysfuctions. Clin Exp Hypertens 2004, 26: 387-398.

14) Minnoci A, Savia G, Lucantoni R, Berselli ME, Tagliaferri M, Calo G, Petroni ML, de Medici C, Viberti GC, Liuzzi A: Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obese Relat Metab Disord 2000, 24: 1139-1144.

15) Fain JN, Balhouth SW, Madan AK: TNF alpha release by the nonfat cells of the human adipose tissue. . Int J Obese Relat Metab Disord 2004, 28: 615-622.

16) Thompson PD, Crouse SF, Goodpaster B, Kelley D, Moyna N, Pescatello L: The acute versus the chronic response to exercise. Med Sci Sports Exerc 2001, 33: S438-45, discussion S452-3.

17) Paffenbarger, RS, Hyde RT, Wing AL, Le IM, Jung DL, Kampert JB: The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Eng J Med 1993, 328:538-545.

18) Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich JJ: Effective exercise modality to reduce insulin resistance in women with Type 2 diabetes. Diabetes Care 2003, 26:2977-2983.

19) McGavock JM, Mandie S, Vonder I, Mulhill I, Lewanczuk RZ, Quinney HA, Taylor DA, Welsh RC, Haykowsky M: Low cardiorespiratory fitness is associated with elevated C-reactive protein levels in women with Type 2 diabetes. Diabetes Care 2004, 27:320-325.

20) Riechman SE, Schoen RE, Weissfeld JL, Thaete FL, & Kriska AM (2002). Association of physical activity and visceral adipose tissue in older women and men. Obesity Research 10(10): 1065-1073.

21) Freedland ES: Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutrition & Metabolism 2004, 1:12doi:10.1186/1743-7075: 1-12.

22) Frisancho AR: Reduced rate of fat oxidation: A metabolic pathway to obesity in the developing nations. Am J Human Biol 2003, 15:522-532.

23) Westman EC, Mavropoulos J, Yancy WS, Volek JS: A review of low-carbohydrate ketogenic diets. Curr Atheroscler Rep 2003, 5: 476-483.

24) Phinney SD, Bistrian BR, Wolfe RR, Blackburn GL: The human metabolic response to chronic ketosis without caloric restriction: physical and biochemical adaptation. Metabolism 1983, 32: 757-768.

25) Sharman MJ, Kraemer WJ, Love DM, Avery NG, Gomez AL, Asheett TP, Volek JS: A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men. J Nutr 2002, 132: 1879-1885.

26) Ebbling CB, Ludwig DS: Treating obesity in youth: should dietary glycemic load be a consideration? Adv Pediatr 2001, 48:179-212.

27) Bujalska IJ, Kumar S, Stewart PM: Does central obesity reflect “Cushing’s disease of the omentum”? Lancet 1997, 349:1210-1213.

28) Bjorntorp P: Endocrine abnormalities in obesity. Diabetes Reviews 1997, 5:

29) Marin P, Arver S: Androgens and abdominal obesity Baillieres Clin Endocrinol Metab 1998, 12:441-451.

30) Jezova D, Vigas M, Tatar P, Kvetnansky R, Nazar K, Kaciuba-Uscilko H, Kozlowski S: Plasma testosterone and catecholamine responses to physical exercise of different intensities in men. Eur J Appl Physiol 1985, 54:62-66.

31) Volek JS,Kraemer WJ, Bush JA, Incledon T, Boetes M: Testosterone and cortisol in relationship to dietary nutrients and resistance exercise. J. Appl. Physiol. 1997, 82(1): 49-54.

32) Walker BR: 11beta-hydroxysteroid dehydrogenase type 1 in obesity. Obes Res 2004, 12:1-3.

33) Kelley DE, Williams KV, Price JE, McKolanis TM, Goodpaster BM, Thaete FL: Plasma fatty acids adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab, 2001, 86:5412-5419.

34) Colberg SR, Simoneau JA, Thaete FL, Kelley DE: Skeletal muscle utilization of free fatty acids in women with visceral obesity. J Clin. Invest. 1995, 95:1846-1853.

_____________________________________________________________________________________

Mark P. Kelly has a doctorate in Exercise Physiology and Education Administration, he has specialties in kinesiology, exercise and nutritional biochemistry, weight management, and endurance athletic physiology. He was a nationally ranked duathlete, body building contest winner, trainer of professional athletes, and personal trainer for 20 years. He is a primary writer for the NFPT certification programs, a teacher in universities, and runs Principle Centered Health Human Performance Services, which specializes in assessments and corporate wellness. He can be reached at [email protected].

About

These resources are for the purpose of personal trainer growth and development through Continuing Education which advances the knowledge of fitness professionals. This article is written for NFPT Certified Personal Trainers to receive Continuing Education Credit (CEC). Please contact NFPT at 800.729.6378 or [email protected] with questions or for more information.